Horizon Therapeutics (HPTX) Earning Somewhat Positive Media Coverage, Report Finds
News stories about Horizon Therapeutics (NASDAQ:HPTX) have been trending somewhat positive on Wednesday, Accern Sentiment reports. The research group identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Horizon Therapeutics earned a daily sentiment score of 0.06 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 47.2492515233581 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Horizon Therapeutics (NASDAQ HPTX) opened at $45.99 on Wednesday. Horizon Therapeutics has a twelve month low of $20.23 and a twelve month high of $46.96. The firm has a market capitalization of $964.29 and a PE ratio of -1,533.00.
ILLEGAL ACTIVITY NOTICE: “Horizon Therapeutics (HPTX) Earning Somewhat Positive Media Coverage, Report Finds” was published by Marea Informative and is owned by of Marea Informative. If you are viewing this news story on another site, it was illegally copied and republished in violation of United States & international trademark & copyright laws. The original version of this news story can be viewed at https://www.mareainformativa.com/2018/03/14/horizon-therapeutics-hptx-receives-daily-coverage-optimism-rating-of-0-06-updated-updated-updated.html.
Horizon Therapeutics, Inc, formerly Hyperion Therapeutics, Inc, is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder.
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.